Ser432

Site Information
FAGAkAIssDMFFGR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 469076

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 )
Disease tissue studied:	breast cancer ( 3 , 6 , 7 , 15 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 6 ) , cervical cancer ( 27 ) , cervical adenocarcinoma ( 27 ) , leukemia ( 17 , 19 ) , acute myelogenous leukemia ( 17 , 19 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 14 ) , acute megakaryoblastic leukemia (M7) ( 14 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 14 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 14 ) , acute myeloblastic leukemia, without maturation (M1) ( 14 ) , lung cancer ( 16 ) , non-small cell lung cancer ( 16 ) , lymphoma ( 8 ) , B cell lymphoma ( 14 ) , Burkitt's lymphoma ( 8 ) , non-Hodgkin's lymphoma ( 14 ) , follicular lymphoma ( 8 ) , mantle cell lymphoma ( 8 ) , pancreatic ductal adenocarcinoma ( 9 ) , multiple myeloma ( 14 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 20 ) , 'pancreatic, ductal'-pancreas ( 9 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 25 ) , 293 (epithelial) ( 30 ) , 293E (epithelial) ( 22 ) , A549 (pulmonary) ( 10 ) , AML-193 (monocyte) ( 14 ) , BJAB (B lymphocyte) ( 8 ) , breast ( 1 , 6 ) , CMK (megakaryoblast) ( 14 ) , CTS (myeloid) ( 14 ) , DOHH2 ('B lymphocyte, precursor') ( 14 ) , FL-18 (B lymphocyte) ( 8 ) , FL-318 (B lymphocyte) ( 8 ) , GM00130 (B lymphocyte) ( 26 ) , H2009 (pulmonary) ( 16 ) , H2077 (pulmonary) ( 16 ) , H2887 (pulmonary) ( 16 ) , H322M (pulmonary) ( 16 ) , HCC2279 (pulmonary) ( 16 ) , HCC366 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 16 ) , HEL (erythroid) ( 14 ) , HeLa (cervical) ( 5 , 13 , 24 , 32 , 33 ) , HeLa S3 (cervical) ( 27 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 7 ) , HMLER ('stem, breast cancer') ( 7 ) , HOP62 (pulmonary) ( 16 ) , HUES-7 ('stem, embryonic') ( 29 ) , HUES-9 ('stem, embryonic') ( 23 ) , JEKO-1 (B lymphocyte) ( 8 ) , Jurkat (T lymphocyte) ( 11 , 21 , 31 ) , K562 (erythroid) ( 13 , 28 ) , Kasumi-1 (myeloid) ( 14 ) , KG-1 (myeloid) ( 14 , 19 ) , MCF-7 (breast cell) ( 3 ) , MV4-11 (macrophage) ( 14 , 17 ) , NCEB-1 (B lymphocyte) ( 8 ) , NCI-H1568 (pulmonary) ( 16 ) , NCI-H157 (pulmonary) ( 16 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H2172 (pulmonary) ( 16 ) , NCI-H322 (pulmonary) ( 16 ) , NCI-H647 (pulmonary) ( 16 ) , OCI-ly1 (B lymphocyte) ( 8 ) , OPM-2 (plasma cell) ( 14 ) , P31/FUJ (erythroid) ( 14 , 17 ) , Raji (B lymphocyte) ( 8 ) , RAMOS (B lymphocyte) ( 8 ) , REC-1 (B lymphocyte) ( 8 ) , RL ('B lymphocyte, precursor') ( 14 ) , RPMI-8266 (plasma cell) ( 14 ) , SKBr3 (breast cell) ( 15 ) , SU-DHL-4 (B lymphocyte) ( 8 ) , SU-DHL-6 (B lymphocyte) ( 14 ) , U266 (plasma cell) ( 14 ) , UPN-1 (B lymphocyte) ( 8 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Treatments:	ischemia ( 6 ) , nocodazole ( 27 ) , PI-103 ( 17 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
6	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
7	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
8	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
9	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
10	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
11	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
12	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
13	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
14	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
15	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
16	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
17	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
18	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
19	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
20	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
21	Mulhern D (2011) CST Curation Set: 12699; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
22	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
23	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
24	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
25	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
26	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
27	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
28	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
29	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
30	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
31	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
32	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
33	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info